menu
    • menu
    [{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix \/ Not Applicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"OLX-07010","moa":"Tau protein","graph1":"Neurology","graph2":"IND Enabling","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oligomerix \/ Not Applicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"OLX07010","moa":"Tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix \/ Not Applicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"OLX-07010","moa":"Tau protein","graph1":"Neurology","graph2":"IND Enabling","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oligomerix \/ Not Applicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"OLX07010","moa":"Tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix \/ Undisclosed"},{"orgOrder":0,"company":"Oligomerix","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"OLX-07010","moa":"Tau protein","graph1":"Neurology","graph2":"IND Enabling","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"Oligomerix \/ National Institute on Aging"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OLX-07010","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oligomerix \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Oligomerix

    Menu

    Oligomerix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer's Dis...

                            Details : OLX-07010 is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process believed to be implicated in the development of Alzheimer’s disease and other neurodegenerative disorders.

                            Brand Name : OLX-07010

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2022

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : National Institute on Aging

                            Deal Size : $3.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Ther...

                            Details : OLX-07010 would potentially fill a significant unmet need with a disease-modifying drug that, if successful, will have a tremendous impact on patient outcomes and reduce the burden on caregivers and society.

                            Brand Name : OLX-07010

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 09, 2022

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institute on Aging

                            Deal Size : $3.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX07010

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $2.7 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development

                            Details : The lead candidate OLX07010, has demonstrated efficacy in animal models of tau-mediated neurodegeneration. Preclinical safety studies are completed and Phase 1a clinical studies are planned to initiate in the third quarter of 2022.

                            Brand Name : OLX-07010

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 03, 2022

                            Lead Product(s) : OLX07010

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $2.7 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer's Disease (CTAD) Conference and Socie...

                            Details : A study was conducted in the tau P301L JNPL3 mouse model for tau aggregation and motor impairment that was aged prior to treatment in order to study the therapeutic effect of OLX-07010.

                            Brand Name : OLX-07010

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2021

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX07010

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Al...

                            Details : OLX07010, has demonstrated efficacy in several animal models of neurodegeneration and, upon completion of its preclinical program in the next couple of months, will start Phase 1 clinical studies in early 2022.

                            Brand Name : OLX07010

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 30, 2021

                            Lead Product(s) : OLX07010

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oligomerix to Present at Alzheimer's Association International Conference

                            Details : Company will be presenting preclinical data on its oral, tau self-association small molecule inhibitor lead program, OLX-07010, at the 2021 Alzheimer's Association International Conference.

                            Brand Name : OLX-07010

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 26, 2021

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Oligomerix

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oligomerix to Present at Clinical Trials on Alzheimer’s Disease Conference & Life Sciences Summit

                            Details : Poster titled "Therapeutic efficacy of a small molecule inhibitor targeting tau self-association in mouse models of tauopathy" will be presented at the 13th Clinical Trials on Alzheimer’s Disease Conference 2020 Digital Event.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 29, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth